• 1
    Therapondos G, Flapan A, Plevris J, Hayes P. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 10: 14411453.
  • 2
    Neal D, Tom B, Luan J, Wareham N, Gimson A, Delriviere, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation 2004; 77: 9399.
  • 3
    Guckelberger O, Bechstein W, Neuhaus R, Luesebrink R, Lemmens H, Kratschmer B, et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997; 11: 6065.
  • 4
    Sheiner P, Magliocca J, Bodian C, Kim-Schluger L, Altaca G, Altaca G, et al. Long-term medical complications in patients surviving ≥5 years after liver transplant. Transplantation 2000; 69: 781789.
  • 5
    Reich D, Rothstein K, Manzarbeitia, Munoz. Common medical issues after liver transplantation. Semin Gastro Dis 1998; 9: 110125.
  • 6
    Johnston S, Morris J, Cramb R, Gunson B, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901906.
  • 7
    Mosca L, Linfante A, Benjamin E, Berra K, Hayes S, Walsh B, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines Circulation 2005; 111: 499510
  • 8
    Anderson K, Wilson P, Odell P, Kannel W. An updated coronary risk profile: A statement for health professionals. AHA Statement 1991; 83: 356362.
  • 9
    Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular muster (PROCAM) study. Circulation 2002; 105: 310315.
  • 10
    Cleeman J. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 19: 24862497.
  • 11
    Grundy S, Cleeman J, Bairey N, Brewer B, Clark L, Hunninghake D, et al. Implications of recent clinical trials for the national Cholesterol Education program adult treatment panel III guidelines Circulation 2004; 110: 227239.
  • 12
    Imagawa D, Dawson S, Holt C, Kirk P, Kaldas F, Shackleton C, et al. Hyperlipidemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin1. Transplantation 1996; 62: 934942.
  • 13
    Holdaas H, Fellstrom B, Jardine A. Clinical practice guidelines for managing dislipidemias in kidney transplant patients: Lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial Am J Transplant 2005; 5: 15741575.
  • 14
    Rabkin J, Corless C, Rosen H, Oylaei A. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595599.
  • 15
    Neal D, Gimson A, Gibbs P, Alexander G. Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight. Liver Transpl 2001; 7: 533539.
  • 16
    Beckebaum S, Cicinnati V, Klein C, Brokalaki E, Yu Z, et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. Transpl Proc 2004; 36: 26712674.
  • 17
    Kniepeiss D, Iberer F, Schaffelner S, Jakoby E, Duller D, Tscheliess, et al. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin Transpl 2004; 18: 642646.
  • 18
    Angelico F, Del Ben M, Francioso S, Monika H, Serena B, Palmieiri G, et al. Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 2003 15: 99102.
  • 19
    Neal D, Brown M, Wilkinson I, Alexander G. Mechanisms of hypertension after liver transplantation. Transplantation 2005; 79: 935940.
  • 20
    Neal D, Brown A, Morris J, Wilkinson I, Byrne C, Alexander G, et al. Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. Transplantation 2004; 77: 748750.
  • 21
    Dikow R, Degenhard M, Kraus T, Sauer K, Schemmer P, Buchler M, et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. Transpl Proc 2004; 36: 15121515.
  • 22
    Munoz S. Long term management of the liver transplant recipient. Med Clin North Am 1996; 80: 11031119.
  • 23
    Gonwa T. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7( Suppl 1): S22S26.
  • 24
    Galioto A, Angeli P, Guarda S, Burra P, Zanus G, Fazolato S, et al. Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. Transpl Proc 2005; 37: 12451247.
  • 25
    Taler S, Textor S, Canzanello J, Schwartz, L, Porayko M, Wiesner R, et al. Hypertension after liver transplantation a predictive role for pretreatment hemodynamics and effects of isradipine on the systemic and renal circulations. Am J Hypert 2000; 13: 231239.
  • 26
    Pungpapong S, Manzarbeitia C, Ortiz J, Reich D, Araya V, Rothstein K, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transplant 2002; 8: 582587.
  • 27
    Di Martini A, Lubna J, Russell S, Dew MA, Fitzgerald M, Jain A, et al. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. Liver Transplant 2005; 11: 679683.
  • 28
    Swartz S, Hays J. Office-based interventions for tobacco dependence. Med Clin North Am 2004; 88: 16231641.
  • 29
    Munoz S. Tobacco use by liver transplant recipients: Grappling with a smoking gun. Liver Transplant 2005; 11: 606609.